<DOC>
	<DOCNO>NCT00507832</DOCNO>
	<brief_summary>The development topical calcineurin inhibitor pimecrolimus result significant improvement treatment atopic dermatitis . In addition , excellent amelioration pruritus could regularly observe . Up , several itchy dermatosis chronic irritative hand dermatitis , rosacea , graft-versus-host-disease , lichen sclerosus , prurigo simplex , scrotal eczema , inverse psoriasis report single case also respond pimecrolimus treatment . In prurigo nodularis , pruritus main symptom immediate importance find effective antipruritic therapy . Pruritus regularly severe therapy refractory topical steroid systemic antihistamine . Capsaicin cream one effective possibility reduce itch disease . However , apply 3 6 time daily , rub clothe induces burn erosion . In addition , since commercial preparation available , prescribed several concentration . The application pimecrolimus seem promise since apply twice daily . Especially prurigo nodularis expect good response could demonstrate single patient . Furthermore publish recently Tacrolimus , another calcineurin inhibitor successfully use treatment six patient prurigo nodularis . This study design compare efficacy safety pimecrolimus 1 % cream hydrocortisone 1 % cream prurigo nodularis investigate mode action antipruritic effect drug .</brief_summary>
	<brief_title>Evaluation Antipruritic Effect Elidel ( Pimecrolimus ) Non-atopic Pruritic Disease</brief_title>
	<detailed_description>Patients treat pimecrolimus cream 1 % hydrocortisone cream 1 % twice daily 8 week diseased skin double-blind , randomize within patient comparison ( left arm pimecrolimus , right arm hydrocortisone vice versa ) . Patients enter 4-week treatment free follow-up period . The overall study duration 12 month . The study population consist representative group 30 adult patient ( 18 - 70 year age ) prurigo nodularis one center Germany . Inclusion criterion - Age : 18 - 70 year - Diagnosis : Prurigo nodularis - Pruritus intensity VAS 3 ( Visual analogue scale 0 10 ) - Nodules arm leg ( target area : arm ) - No effective current external internal antipruritic medication - Signed informed consent Exclusion criterion - prurigo nodularis massive excoriation and/or local infection - atopic dermatitis , predisposition atopic dermatitis - Itch intensity VAS 4 ( visual analoge scale 0 10 ) - Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG test . Pregnancy rule state study b-subunit HCG test . - Females childbearing potential practicing medically approve , highly effective ( low failure rate ) method contraception least 4 week end treatment . 'Medically approve ' contraception may include implant , injectables , combine oral contraceptive , IUDs ( e.g . intrauterine device ) , sexual abstinence woman vasectomize partner . - active psychosomatic psychiatric diseases - History active malignancy organ system - actual disease need therapy may induce pruritus ( e.g . deficiency iron , zinc ) - Systemic immunosuppression - Topical use tacrolimus , pimecrolimus , steroid capsaicin within 2 week prior study entry - current past ( within 2 week prior study entry ) systemic use antihistamine , steroid , cyclosporin A immunosuppressant , paroxetin , fluvoxamine ( selective serotonin reuptake- inhibitor , study possible case medication since 6 month due depression without Antipruritic effect ) naltrexone UV-therapy . - wound healing disturbance , disposition keloid , current medication lead increase bleeding procedure e.g . acetylsalicylic acid ( ASS ) , marcumar ( suction blister possible ) - History hypersensitivity pimecrolimus 1 % cream hydrocortisone 1 % cream - Participation clinical study within last 4 week</detailed_description>
	<mesh_term>Prurigo</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antipruritics</mesh_term>
	<criteria>Age : 18 70 year Diagnosis : Prurigo nodularis Pruritus intensity VAS 3 ( Visual analoge scale 0 10 ) Nodules arm leg ( target area : arm ) No effective current external internal antipruritic medication Signed informed consent prurigo nodularis massive excoriation and/or local infection atopic dermatitis , predisposition atopic dermatitis Itch intensity VAS 4 ( visual analoge scale 0 10 ) Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG test . Pregnancy rule state study bsubunit HCG test . Females childbearing potential practicing medically approve , highly effective ( low failure rate ) method contraception least 4 week end treatment . 'Medically approve ' contraception may include implant , injectables , combine oral contraceptive , IUDs ( e.g . intrauterine device ) , sexual abstinence woman vasectomize partner . active psychosomatic psychiatric disease History active malignancy organ system actual disease need therapy may induce pruritus ( e.g . deficiency iron , zinc ) Systemic immunosuppression Topical use tacrolimus , pimecrolimus , steroid capsaicin within 2 week prior study entry current past ( within 2 week prior study entry ) systemic use antihistamine , steroid , cyclosporin A immunosuppressant , paroxetin , fluvoxamine ( selective serotonin reuptake inhibitor , study possible case medication since 6 month due depression without Antipruritic effect ) naltrexone UVtherapy . wound heal disturbance , disposition keloid , current medication lead increase bleeding procedure e.g . acetylsalicylic acid ( ASS ) , marcumar ( suction blister possible ) History hypersensitivity pimecrolimus 1 % cream hydrocortisone 1 % cream Participation clinical study within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Prurigo nodularis</keyword>
</DOC>